- Hem
- Om universitetet
- Hitta person
- Peter Larsson
Peter Larsson
Postdoktor
Avdelningen för LaboratoriemedicinOm Peter Larsson
Peter Larsson disputerade inom ämnet onkologi, den 13 juni 2023
Titeln på hans avhandling är – The proteasome as a target for cancer therapy
Läs en kort populärvetenskaplig artikel om avhandlingen - Proteasomen som måltavla för cancerbehandling
-
Multi-omics analysis identifies repurposing bortezomib in the treatment of kidney-, nervous system-, and hematological
cancers
Peter Larsson, Maxim Olsson, Sithumini Sarathchandra, Anna Fäldt Beding, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2024 -
Integrated transcriptomics- and structure-based drug repositioning identifies drugs with proteasome inhibitor
properties
Peter Larsson, MC Rosa, Benedetta Righino, Maxim Olsson, Bogdan Iulius Florea, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2024 -
Repurposing proteasome inhibitors for improved treatment of triple-negative breast
cancer
Peter Larsson, Daniella Pettersson, Maxim Olsson, Sithumini Sarathchandra, Alexandra Abramsson, Henrik Zetterberg, Ella Ittner, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Cell death discovery - 2024 -
Cancer stem cells are prevalent in the basal-like 2 and mesenchymal triple-negative breast cancer subtypes in
vitro
Maxim Olsson, Peter Larsson, Junko Johansson, Vasu R. Sah, Toshima Z Parris
Frontiers in Cell and Developmental Biology - 2023 -
The proteasome as a target for cancer
therapy
Peter Larsson
2023 -
Optimization of Cell Viability Assays for Drug Sensitivity
Screens.
Peter Larsson, Toshima Z Parris
Methods in molecular biology (Clifton, N.J.) Vol. 2644 - 2023 -
Pan-cancer analysis of genomic and transcriptomic data reveals the prognostic relevance of human proteasome genes in different cancer
types.
Peter Larsson, Daniella Pettersson, Hanna Engqvist, Elisabeth Werner Rönnerman, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
BMC cancer - 2022 -
Pan-cancer analysis identifies BIRC5 as a prognostic
biomarker.
Anna Fäldt Beding, Peter Larsson, Khalil Helou, Zakaria Einbeigi, Toshima Z Parris
BMC Cancer - 2022 -
Integrative genomics approach identifies molecular features associated with early-stage ovarian carcinoma
histotypes.
Hanna Engqvist, Toshima Z Parris, Jana Biermann, Elisabeth Werner Rönnerman, Peter Larsson, Karin Sundfeldt, Anikó Kovács, Per Karlsson, Khalil Helou
Scientific reports - 2020 -
Optimization of cell viability assays to improve replicability and reproducibility of cancer drug sensitivity
screens.
Peter Larsson, Hanna Engqvist, Jana Biermann, Elisabeth Werner Rönnerman, Eva Forssell-Aronsson, Anikó Kovács, Per Karlsson, Khalil Helou, Toshima Z Parris
Scientific Reports - 2020